Limits...
Biomarker-based detection of asthma-COPD overlap syndrome in COPD populations.

Tamada T, Sugiura H, Takahashi T, Matsunaga K, Kimura K, Katsumata U, Takekoshi D, Kikuchi T, Ohta K, Ichinose M - Int J Chron Obstruct Pulmon Dis (2015)

Bottom Line: Asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) was proposed by the science committees of both Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD).However, the definition of ACOS has remained unclear all over the world, and the prevalence rate of ACOS is basically dependent on the patient's symptoms or the physician's opinion, based on questionnaire testing.The results from the current study should be useful to identify the subgroup requiring early intervention by inhaled corticosteroids/long-acting beta agonist combination in COPD in order to improve the long-term management for ACOS.

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

ABSTRACT
Asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) was proposed by the science committees of both Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD). However, the definition of ACOS has remained unclear all over the world, and the prevalence rate of ACOS is basically dependent on the patient's symptoms or the physician's opinion, based on questionnaire testing. In the current case report, we investigated the prevalence rate of COPD patients with high levels of fractional exhaled nitric oxide (FENO) or immunoglobulin E (IgE) as candidate markers of ACOS in COPD, as a multicenter, cross-sectional study. Outpatients with COPD were enrolled from Tohoku University Hospital, Sendai, Japan, and five hospitals (Tohoku University Hospital, Sendai, Japan; NTT East Tohoku Hospital, Sendai, Japan; Wakayama Medical University Hospital, Kimiidera, Japan; Hiraka General Hospital, Yokote, Japan; Iwate Prefectural Isawa Hospital, Oshu, Japan) with pulmonary physicians from March 1, 2013 to February 28, 2014. When they were estimated using 35 ppb as the cutoff value of FENO, the prevalence rate of ACOS was 16.3% in COPD. When estimated by both FENO and IgE, the high-FENO/high-IgE group was 7.8% in COPD. To the best of our knowledge, this study is the first to detect the prevalence rate of ACOS in COPD populations by using objective biomarkers. The results from the current study should be useful to identify the subgroup requiring early intervention by inhaled corticosteroids/long-acting beta agonist combination in COPD in order to improve the long-term management for ACOS.

No MeSH data available.


Related in: MedlinePlus

Histogram of total IgE values in the subjects.Notes: A total of 230 (69.8%) of the 331 COPD patients were measured for total IgE before the enrollment. When the cutoff value of IgE was set at 173 IU/mL, there were 82 (35.7%) patients with a high level of total IgE out of 230 COPD patients.Abbreviation: IgE, immunoglobulin E.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4608617&req=5

f2-copd-10-2169: Histogram of total IgE values in the subjects.Notes: A total of 230 (69.8%) of the 331 COPD patients were measured for total IgE before the enrollment. When the cutoff value of IgE was set at 173 IU/mL, there were 82 (35.7%) patients with a high level of total IgE out of 230 COPD patients.Abbreviation: IgE, immunoglobulin E.

Mentions: A subtotal of 230 (69.8%) of the 331 COPD patients had been measured for total IgE before their enrollment in the current study. A histogram of their total IgE values is shown in Figure 2. The cutoff value of IgE was set at 173 IU/mL in the current survey. The median value of total IgE was 91 IU/mL (IQR, 27–287 IU/mL). Out of 230 COPD patients, 82 (35.7%) patients had high levels of total IgE. These findings indicated that 35.7% of patients had atopic factors in COPD.


Biomarker-based detection of asthma-COPD overlap syndrome in COPD populations.

Tamada T, Sugiura H, Takahashi T, Matsunaga K, Kimura K, Katsumata U, Takekoshi D, Kikuchi T, Ohta K, Ichinose M - Int J Chron Obstruct Pulmon Dis (2015)

Histogram of total IgE values in the subjects.Notes: A total of 230 (69.8%) of the 331 COPD patients were measured for total IgE before the enrollment. When the cutoff value of IgE was set at 173 IU/mL, there were 82 (35.7%) patients with a high level of total IgE out of 230 COPD patients.Abbreviation: IgE, immunoglobulin E.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4608617&req=5

f2-copd-10-2169: Histogram of total IgE values in the subjects.Notes: A total of 230 (69.8%) of the 331 COPD patients were measured for total IgE before the enrollment. When the cutoff value of IgE was set at 173 IU/mL, there were 82 (35.7%) patients with a high level of total IgE out of 230 COPD patients.Abbreviation: IgE, immunoglobulin E.
Mentions: A subtotal of 230 (69.8%) of the 331 COPD patients had been measured for total IgE before their enrollment in the current study. A histogram of their total IgE values is shown in Figure 2. The cutoff value of IgE was set at 173 IU/mL in the current survey. The median value of total IgE was 91 IU/mL (IQR, 27–287 IU/mL). Out of 230 COPD patients, 82 (35.7%) patients had high levels of total IgE. These findings indicated that 35.7% of patients had atopic factors in COPD.

Bottom Line: Asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) was proposed by the science committees of both Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD).However, the definition of ACOS has remained unclear all over the world, and the prevalence rate of ACOS is basically dependent on the patient's symptoms or the physician's opinion, based on questionnaire testing.The results from the current study should be useful to identify the subgroup requiring early intervention by inhaled corticosteroids/long-acting beta agonist combination in COPD in order to improve the long-term management for ACOS.

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

ABSTRACT
Asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) was proposed by the science committees of both Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD). However, the definition of ACOS has remained unclear all over the world, and the prevalence rate of ACOS is basically dependent on the patient's symptoms or the physician's opinion, based on questionnaire testing. In the current case report, we investigated the prevalence rate of COPD patients with high levels of fractional exhaled nitric oxide (FENO) or immunoglobulin E (IgE) as candidate markers of ACOS in COPD, as a multicenter, cross-sectional study. Outpatients with COPD were enrolled from Tohoku University Hospital, Sendai, Japan, and five hospitals (Tohoku University Hospital, Sendai, Japan; NTT East Tohoku Hospital, Sendai, Japan; Wakayama Medical University Hospital, Kimiidera, Japan; Hiraka General Hospital, Yokote, Japan; Iwate Prefectural Isawa Hospital, Oshu, Japan) with pulmonary physicians from March 1, 2013 to February 28, 2014. When they were estimated using 35 ppb as the cutoff value of FENO, the prevalence rate of ACOS was 16.3% in COPD. When estimated by both FENO and IgE, the high-FENO/high-IgE group was 7.8% in COPD. To the best of our knowledge, this study is the first to detect the prevalence rate of ACOS in COPD populations by using objective biomarkers. The results from the current study should be useful to identify the subgroup requiring early intervention by inhaled corticosteroids/long-acting beta agonist combination in COPD in order to improve the long-term management for ACOS.

No MeSH data available.


Related in: MedlinePlus